According to a new market report published by Lucintel, the future of the companion diagnostic market looks promising with opportunities in the pharmaceutical and biopharmaceutical companies and reference laboratories. The companion diagnostic market is expected to grow with a CAGR of 20% from 2019 to 2024. The major drivers for this market are improvements in regulatory guidelines, growing need for targeted therapies, rising cancer incidence, and increasing collaborations and partnerships for companion diagnostic test development.
To download report brochure, please go to https://www.lucintel.com/companion-diagnostic-market.aspx and click "report brochure" tab from the menu.
Within the companion diagnostic market, oncology and neurology are the major segment by indication. The oncology segment is the largest segment of the companion diagnostic market.
Polymerase chain reaction (PCR), immunohistochemistry (IHC), In situ hybridization (ISH), and next-generation sequencing are the major technology segment of the companion diagnostic market.
North America will remain the largest region over the forecast period due to increasing technological advancements aimed at developing companion diagnostic tests for new indications such as neurology, infectious diseases, and so on.
F. Hoffmann-La Roche, Agilent Technologies, Qiagen N.V., Thermo Fisher Scientific, Abbott Laboratories, Biomérieux, Danaher Corporation, Illumina ,Myriad Genetics, Arup Laboratories, Sysmex, Hologic, Almac Group, and Abnova are among the major manufacturers of companion diagnostic.
Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the companion diagnostic market by product and service, technology, indication, end use, and region. Lucintel has prepared a comprehensive research report titled "Companion Diagnostic Market 2019-2024: Trends, Forecast, and Opportunity Analysis". This Lucintel report serves as a catalyst for growth strategy as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes a forecast for the companion diagnostic market by product and service, technology, indication, end use, and region as follows:
By Product and Service [$M shipment analysis for 2013 – 2024]:
Assays & Reagents
Software & Services
By Technology [$M shipment analysis for 2013 – 2024]:
Polymerase Chain Reaction (PCR)
Immunohistochemistry (IHC)
In Situ Hybridization (ISH)
Next-generation Sequencing
Other Technologies
By Indication [$M shipment analysis for 2013 – 2024]:
Oncology
Neurology
Others
By End Use [$M shipment analysis for 2013 – 2024]:
Pharmaceutical and Biopharmaceutical Companies
Reference Lab
Other End Users
By Region [$M shipment analysis for 2013 – 2024]:
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Asia-Pacific
ROW
This 150-page research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link https://www.lucintel.com/companion-diagnostic-market.aspx or helpdesk@lucintel.com.
About Lucintel
Lucintel, the premier global Management Consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, Growth Consulting, M&A, and Due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.